Company:  AYTU BIOSCIENCE, INC (AYTU)
Form Type:  10-K
Filing Date:  9/26/2019 
CIK:  0001385818 
Address:  373 INVERNESS PARKWAY
SUITE 206
 
City, State, Zip:  ENGLEWOOD, Colorado 80112 
Telephone:  (720) 437-6580 
Fiscal Year:  06/30 
Last Trade
Last Trade: 
$0.83  
Change: 
0.1346 (19.48%)  
Trade Time: 
Dec 12  
Market Cap: 
$17.13M
Trade AYTU now with

© 2019  
Description of Business
We are a specialty pharmaceutical company focused on identifying, acquiring, and commercializing novel products that address significant patient needs. We have multiple FDA-approved products on the market, and we seek to build a portfolio of novel therapeutics that serve large medical needs, across a range of conditions, through our in-house commercial team. Our commercial infrastructure consists of a U.S.-based specialty sales force and an international distribution network with presence in approximately fifty countries. We currently are focused on commercialization of four products, (i) Natesto®, a testosterone replacement therapy, or TRT, (ii) Tuzistra®XR, a codeine based antitussive, (iii) ZolpiMistTM, a short-term insomnia treatment and (iv), MiOXSYS®, a novel in vitro diagnostic system for male infertility assessment.
Register and access this filing in:     
  FORM 10-K
    PART I
      Item 1. Business
      Item 1A. Risk Factors
      Item 1B. Unresolved Staff Comments
      Item 2. Properties
      Item 3. Legal Proceedings
      Item 4. Mine Safety Disclosures
    PART II
      Item 5. Market for Registrant's Common Equity, Related ...
      Item 6.
      Item 7.
        Overview, Liquidity and Capital Resources
        Results of Operations
      Item 7A. Quantitative and Qualitative Disclosures about ...
      Item 8.
      Item 9.
      Controls and Procedures
    PART III
      Item 10.
        NAME AND TITLE
      Item 11.
        COMPENSATION TABLE
      Item 12.
        BENEFICIAL OWNERS
      Item 13.
    PART IV
    SIGNATURES
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
    Report of Independent Registered Public Accounting Firm
    Report of Independent Public Accounting Firm
    BALANCE SHEET
    INCOME STATEMENT
    STOCKHOLDERS EQUITY
    CASH FLOW
    Notes to the Financial Statements
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 23.2
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31
    CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO
  EXHIBIT 31.2
    CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO
  EXHIBIT 32.1
    CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF ...